Qilu Pharmaceutical Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 1992-08-21
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.qilu-pharma.com
A Phase 3 Clinical Study of QLM3004 in Delaying Myopia in Children
- Conditions
- Interventions
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 735
- Registration Number
- NCT06151587
- Locations
- 🇨🇳
The Affiliated Eye Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06058000
- Locations
- 🇨🇳
The First Hospital of China Medical University, Shenyang, Liaoning, China
🇨🇳Dermatology Hospital of Shandong First Medical University, Jinan, Shandong, China
A Study of QL1706H in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT06047431
A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 115
- Registration Number
- NCT06041035
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Study of QLF3108 in Participants With Advanced Solid Tumor
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 78
- Registration Number
- NCT06019013
- Locations
- 🇨🇳
Chinese People's Liberation Army (PLA) General Hospital, Beijing, Beijing, China
A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 668
- Registration Number
- NCT05976568
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
🇨🇳Nanjing Tianyinshan Hospital, Nanjing, Jiangsu, China
Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT05973149
- Locations
- 🇨🇳
Department of Urology, Peking University First Hospital, Beijing, Beijign, China
🇨🇳Department of Urology, Drum Tower Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu, China
Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 478
- Registration Number
- NCT05950516
- Locations
- 🇨🇳
Shandong Provincial Hospital, Jinan, Shandong, China
Safety, Tolerability, and Pharmacokinetic Study of QLM3003 in Healthy Adult Subjects
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05932888
- Locations
- 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT05920876
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China